- Home
- DXR vs HRTX Comparison
DXR vs HRTX Comparison
Compare DXR & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | HRTX |
|---|---|---|
| Founded | 1970 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 54.1M |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DXR | HRTX |
|---|---|---|
| Price | $8.48 | $0.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 4.5M |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,446,345.00 | ★ $154,904,000.00 |
| Revenue This Year | $44,489.33 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ 7.36 |
| 52 Week Low | $8.24 | $0.26 |
| 52 Week High | $14.76 | $1.58 |
Technical Indicators
Market Signals| Indicator | DXR | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.42 | 49.48 |
| Support Level | N/A | $0.28 |
| Resistance Level | $12.07 | $0.34 |
| Average True Range (ATR) | 0.34 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 19.79 | 38.23 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.